Ancestry informative genetic variants associated with tobacco metabolic and detoxification capacity measured by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) among smokers - Scorecard - MDSpire

Ancestry informative genetic variants associated with tobacco metabolic and detoxification capacity measured by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) among smokers

  • By

  • Oladimeji Lanade

  • Zhongxuan He

  • Yan Zhou

  • Elizabeth Blackman

  • Denise Gibbs

  • Sharon Harrison

  • Karthik Devarajan

  • Mark Andrake

  • Roland L. Dunbrack

  • Gerald Nkogbu

  • Aditi Wagh

  • Michael Slifker

  • Cherie Erkmen

  • Freda Patterson

  • Aditi Satti

  • Heather-Dawn Lawson-Myers

  • Robin Roberts

  • Don Mitchell

  • Jeffery C. Liu

  • Joel Erblich

  • Camille Ragin

  • July 14, 2026

Share

Clinical Scorecard: Genetic Variants Informing Ancestry Linked to Tobacco Metabolism and Detoxification Capacity as Assessed by 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in Smokers

At a Glance

CategoryDetail
ConditionTobacco-related cancers
Key MechanismsGenetic polymorphisms affecting tobacco metabolism and detoxification
Target PopulationSmokers, particularly Black and White Americans
Care SettingCommunity and clinical settings

Key Highlights

  • Tobacco use is the largest avoidable cause of cancer mortality worldwide.
  • Significant differences in lung cancer incidence and mortality rates exist between Black and White Americans.
  • Genetic ancestry may influence the metabolism of tobacco carcinogens.
  • Higher metabolic efficiency of NNAL has been reported among White Americans compared to Black Americans.
  • The study focuses on the association of genetic ancestry with NNAL metabolism in smokers.

Guideline-Based Recommendations

Diagnosis

  • Consider genetic ancestry factors when assessing lung cancer risk in smokers.

Management

  • Monitor tobacco metabolism through genetic testing in diverse populations.

Monitoring & Follow-up

  • Assess urinary NNAL metabolites as a measure of tobacco exposure and metabolism.

Risks

  • Increased risk of lung cancer associated with genetic variants in tobacco metabolism.

Patient & Prescribing Data

Smokers aged 18 or older with no known cancer diagnosis.

Understanding genetic variants may inform personalized smoking cessation strategies.

Clinical Best Practices

  • Engage community-based strategies for participant recruitment in cancer studies.
  • Utilize culturally tailored survey instruments for diverse populations.

Related Resources & Content

Original Source(s)

Ancestry informative genetic variants associated with tobacco metabolic and detoxification capacity measured by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) among smokers

  • by Oladimeji Lanade, Zhongxuan He, Yan Zhou, Elizabeth Blackman, Denise Gibbs, Sharon Harrison, Karthik Devarajan, Mark Andrake, Roland L. Dunbrack, Gerald Nkogbu, Aditi Wagh, Michael Slifker, Cherie Erkmen, Freda Patterson, Aditi Satti, Heather-Dawn Lawson-Myers, Robin Roberts, Don Mitchell, Jeffery C. Liu, Joel Erblich, Camille Ragin

  • July 14, 2026

Related Content

Single-cell and spatial omics in non-small cell lung cancer: dissecting metabolic reprogramming and tumor-immune ecosystems for precision pharmacology

Outcomes following different thermal ablation strategies in patients with oligometastatic colorectal lung metastases

Cost-Effectiveness of Universal Low-Dose Computed Tomographic Lung Cancer Screening in Singapore